Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial

The trial compared zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenstr öm macroglobulinemia.

Source: CancerNetwork - June 8, 2020 Category: Cancer & Oncology Authors: Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA Source Type: news